662 related articles for article (PubMed ID: 19424068)
1. Denosumab update.
Lewiecki EM
Curr Opin Rheumatol; 2009 Jul; 21(4):369-73. PubMed ID: 19424068
[TBL] [Abstract][Full Text] [Related]
2. Denosumab in postmenopausal women with low bone mineral density.
McClung MR; Lewiecki EM; Cohen SB; Bolognese MA; Woodson GC; Moffett AH; Peacock M; Miller PD; Lederman SN; Chesnut CH; Lain D; Kivitz AJ; Holloway DL; Zhang C; Peterson MC; Bekker PJ;
N Engl J Med; 2006 Feb; 354(8):821-31. PubMed ID: 16495394
[TBL] [Abstract][Full Text] [Related]
3. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Wensel TM; Iranikhah MM; Wilborn TW
Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
[TBL] [Abstract][Full Text] [Related]
4. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
Kendler DL; Roux C; Benhamou CL; Brown JP; Lillestol M; Siddhanti S; Man HS; San Martin J; Bone HG
J Bone Miner Res; 2010 Jan; 25(1):72-81. PubMed ID: 19594293
[TBL] [Abstract][Full Text] [Related]
5. Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate.
Beck TJ; Lewiecki EM; Miller PD; Felsenberg D; Liu Y; Ding B; Libanati C
J Clin Densitom; 2008; 11(3):351-9. PubMed ID: 18495508
[TBL] [Abstract][Full Text] [Related]
6. Denosumab for the reduction of bone loss in postmenopausal osteoporosis: a review.
Bridgeman MB; Pathak R
Clin Ther; 2011 Nov; 33(11):1547-59. PubMed ID: 22108301
[TBL] [Abstract][Full Text] [Related]
7. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
Lewiecki EM; Miller PD; McClung MR; Cohen SB; Bolognese MA; Liu Y; Wang A; Siddhanti S; Fitzpatrick LA;
J Bone Miner Res; 2007 Dec; 22(12):1832-41. PubMed ID: 17708711
[TBL] [Abstract][Full Text] [Related]
8. Denosumab for joints and bones.
Lewiecki EM
Curr Rheumatol Rep; 2009 Jul; 11(3):196-201. PubMed ID: 19604464
[TBL] [Abstract][Full Text] [Related]
9. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
[TBL] [Abstract][Full Text] [Related]
10. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis.
Moen MD; Keam SJ
Drugs Aging; 2011 Jan; 28(1):63-82. PubMed ID: 21174488
[TBL] [Abstract][Full Text] [Related]
11. Treatment of osteoporosis with denosumab.
Lewiecki EM
Maturitas; 2010 Jun; 66(2):182-6. PubMed ID: 20236778
[TBL] [Abstract][Full Text] [Related]
12. Denosumab--an emerging treatment for postmenopausal osteoporosis.
Lewiecki EM
Expert Opin Biol Ther; 2010 Mar; 10(3):467-76. PubMed ID: 20095877
[TBL] [Abstract][Full Text] [Related]
13. Denosumab in osteoporosis and oncology.
Burkiewicz JS; Scarpace SL; Bruce SP
Ann Pharmacother; 2009 Sep; 43(9):1445-55. PubMed ID: 19622756
[TBL] [Abstract][Full Text] [Related]
14. [Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis].
Bruhn C
Med Monatsschr Pharm; 2010 Oct; 33(10):370-5. PubMed ID: 21072910
[TBL] [Abstract][Full Text] [Related]
15. Clinical use of denosumab for the treatment for postmenopausal osteoporosis.
Lewiecki EM
Curr Med Res Opin; 2010 Dec; 26(12):2807-12. PubMed ID: 21050058
[TBL] [Abstract][Full Text] [Related]
16. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
Josse R; Khan A; Ngui D; Shapiro M
Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
[TBL] [Abstract][Full Text] [Related]
17. Denosumab for treatment of postmenopausal osteoporosis.
Chitre M; Shechter D; Grauer A
Am J Health Syst Pharm; 2011 Aug; 68(15):1409-18. PubMed ID: 21785030
[TBL] [Abstract][Full Text] [Related]
18. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Bone HG; Bolognese MA; Yuen CK; Kendler DL; Wang H; Liu Y; San Martin J
J Clin Endocrinol Metab; 2008 Jun; 93(6):2149-57. PubMed ID: 18381571
[TBL] [Abstract][Full Text] [Related]
19. Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases.
Delmas PD
J Clin Densitom; 2008; 11(2):325-38. PubMed ID: 18375161
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis.
von Keyserlingk C; Hopkins R; Anastasilakis A; Toulis K; Goeree R; Tarride JE; Xie F
Semin Arthritis Rheum; 2011 Oct; 41(2):178-86. PubMed ID: 21616520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
